The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
Olympic swimmer Ryan Lochte has responded to online speculation and comments suggesting he is 'unrecognizable.' He attributes the perceived changes to the natural process of aging and a recent, unexpected hair dye incident.
Apotex Inc. has launched Apo-Semaglutide Injection™, a generic version of Ozempic®, in Canada. This development brings a more affordable treatment option for type 2 diabetes management to Canadian patients and healthcare providers.
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but understanding your body's response is key. Learn how innovative health monitors can help you track progress and manage side effects effectively.
The revolutionary Wegovy pill offers a needle-free approach to GLP-1 weight loss therapy. Discover its pricing, how it compares to injectables, and how programs are working to make this effective treatment more accessible.
Researchers at UC Riverside have uncovered promising data linking cannabis oil to improved metabolic function and weight loss in mice, sparking debate about its potential as a future therapy alongside GLP-1 medications.
Explore the critical safety differences between compounded GLP-1 medications and FDA-approved treatments. Understand the role of new access programs in combating unsafe alternatives.
The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
New Zealand's Pharmac funding agency has moved semaglutide (Wegovy) to its investment list. Here is what this means for eligibility, costs, and access.
